These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 23819583)

  • 1. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis.
    Kirkham BW; Kavanaugh A; Reich K
    Immunology; 2014 Feb; 141(2):133-42. PubMed ID: 23819583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis.
    Blauvelt A; Chiricozzi A
    Clin Rev Allergy Immunol; 2018 Dec; 55(3):379-390. PubMed ID: 30109481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease.
    Mitra A; Raychaudhuri SK; Raychaudhuri SP
    Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():21-33. PubMed ID: 25398489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis.
    Chiricozzi A
    Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():9-20. PubMed ID: 25398488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psoriasis: rationale for targeting interleukin-17.
    Girolomoni G; Mrowietz U; Paul C
    Br J Dermatol; 2012 Oct; 167(4):717-24. PubMed ID: 22716185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?
    van Baarsen LG; Lebre MC; van der Coelen D; Aarrass S; Tang MW; Ramwadhdoebe TH; Gerlag DM; Tak PP
    Arthritis Res Ther; 2014 Aug; 16(4):426. PubMed ID: 25146432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management.
    Rodríguez-Cerdeira C; González-Cespón JL; Martínez-Herrera E; Carnero-Gregorio M; López-Barcenas A; Sergeev A; Saunte DM
    Ital J Dermatol Venerol; 2021 Oct; 156(5):545-557. PubMed ID: 33026212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin 17A: toward a new understanding of psoriasis pathogenesis.
    Lynde CW; Poulin Y; Vender R; Bourcier M; Khalil S
    J Am Acad Dermatol; 2014 Jul; 71(1):141-50. PubMed ID: 24655820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis.
    Hueber W; Patel DD; Dryja T; Wright AM; Koroleva I; Bruin G; Antoni C; Draelos Z; Gold MH; ; Durez P; Tak PP; Gomez-Reino JJ; ; Foster CS; Kim RY; Samson CM; Falk NS; Chu DS; Callanan D; Nguyen QD; ; Rose K; Haider A; Di Padova F
    Sci Transl Med; 2010 Oct; 2(52):52ra72. PubMed ID: 20926833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-17 and innate immunity in infections and chronic inflammation.
    Isailovic N; Daigo K; Mantovani A; Selmi C
    J Autoimmun; 2015 Jun; 60():1-11. PubMed ID: 25998834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes.
    Hot A; Miossec P
    Ann Rheum Dis; 2011 May; 70(5):727-32. PubMed ID: 21345813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications.
    von Stebut E; Boehncke WH; Ghoreschi K; Gori T; Kaya Z; Thaci D; Schäffler A
    Front Immunol; 2019; 10():3096. PubMed ID: 32010143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [IL-17A and IL-17F: from discovery to target of biologics - an illustrative example of translational research].
    Robert M; Miossec P
    Biol Aujourdhui; 2024; 218(1-2):33-39. PubMed ID: 39007775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Responsiveness of Serum C-Reactive Protein, Interleukin-17A, and Interleukin-17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double-Blind, Placebo-Controlled Trials.
    Siebert S; Sweet K; Dasgupta B; Campbell K; McInnes IB; Loza MJ
    Arthritis Rheumatol; 2019 Oct; 71(10):1660-1669. PubMed ID: 31070869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study.
    Schett G; Chen W; Gao S; Chakravarty SD; Shawi M; Lavie F; Zimmermann M; Sharaf M; Coates LC; Siebert S
    Arthritis Res Ther; 2023 Aug; 25(1):150. PubMed ID: 37587493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.
    Glatt S; Baeten D; Baker T; Griffiths M; Ionescu L; Lawson ADG; Maroof A; Oliver R; Popa S; Strimenopoulou F; Vajjah P; Watling MIL; Yeremenko N; Miossec P; Shaw S
    Ann Rheum Dis; 2018 Apr; 77(4):523-532. PubMed ID: 29275332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologics for psoriasis: What is new?
    Özyurt K; Ertaş R; Atasoy M
    Dermatol Ther; 2019 May; 32(3):e12916. PubMed ID: 30972872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secukinumab: first global approval.
    Sanford M; McKeage K
    Drugs; 2015 Feb; 75(3):329-38. PubMed ID: 25648267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The new era for the treatment of psoriasis and psoriatic arthritis: perspectives and validated strategies.
    Novelli L; Chimenti MS; Chiricozzi A; Perricone R
    Autoimmun Rev; 2014 Jan; 13(1):64-9. PubMed ID: 24021172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors.
    Emond B; Ellis LA; Chakravarty SD; Ladouceur M; Lefebvre P
    Curr Med Res Opin; 2019 Oct; 35(10):1751-1759. PubMed ID: 31106607
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 32.